EU GMP Complaints and Recalls Training: Chapter 8 in Practice

Opens with a pharmacist in Madrid reporting a problem with your tablets, and who must know, and how fast. Covers two European cases: EMA's July 2018 review of valsartan after the NDMA impurity was found in an active substance from China, and EMA's October 2023 alert on falsified Ozempic pens found at EU wholesalers, detected because scanned serial numbers showed as inactive. Turns them into four questions about assessment, extent, decisions and telling the authorities. Introduces JKL Pharma's sites in Mumbai and Singapore and JKL Pharma Europe in Dublin, with its Qualified Person. Gives the map of what Chapter 8 covers, clears three myths, and outlines the ten modules, final exam and certificate. It ends with a recap and three practice questions.

What you will be able to do

• Explain what Chapter 8 of the EU GMP Guide asks a company to do
• Turn a real defect case into questions for your own system
• Describe how the course and final exam work

Why it matters

Seeing how real defects spread across markets helps you check that your own complaints system would catch them early.

Practice: Practice: Complaints and recalls: why Chapter 8 matters · 3 questions

Starts at JKL Pharma Europe in Dublin, where a Vienna wholesaler reports amoxicillin capsules with the wrong strength on the leaflet, from a batch sold in Austria, Germany and Ireland, and asks who must tell whom. Covers the three layers: EU law in Directive 2017/1572 and Directive 2001/83/EC, the GMP Guide in Chapter 1 and in detail in Chapter 8, and the procedures authorities use, including EMA's defective product report form. Explains the duties of manufacturers, holders, wholesalers and authorities, risk classification of defects, and the rapid alert system. Shows an example process map, clears three myths, and warns of the gap when manufacturer and holder each assume the other told the authority. It ends with a recap and three practice questions.

What you will be able to do

• Name the EU laws and GMP chapters that set duties for defects
• Explain who must tell whom across the supply chain
• Describe how authorities classify defects and share alerts

Why it matters

Knowing where each duty sits stops the manufacturer and holder each assuming the other has told the authority.

Practice: Practice: The EU framework at a glance · 3 questions

Opens with a call to JKL's Paris sales office from its biggest French customer about ceftriaxone vials that did not dissolve fully, where sales wants a quiet replacement and quality wants an assessment of a possible under-dose. Covers trained, experienced people who manage defects and decide on recalls, independent of sales and marketing unless justified, and making the Qualified Person who certified the batch formally aware, in a documented way and in time. Explains enough resources, defect teams, central handling, logging every call and email with the authority in the defect file, and roles documented in contracts, illustrated by a Milan contract manufacturer working for three holders. Clears three myths about people and organisation. It ends with a recap and three practice questions.

What you will be able to do

• Explain why defect decisions sit with people independent of sales
• Make sure the Qualified Person is formally informed in good time
• Document defect roles internally and in contracts

Why it matters

Clear, independent roles stop a quiet replacement hiding a defect that could reach more patients.

Practice: Practice: People and organisation · 3 questions

Starts with a Madrid pharmacist calling JKL Pharma Europe about an amoxicillin carton with blurred print that failed scanning: a printing fault, or a falsified pack in the supply chain. Covers paragraph 8.5 and written procedures for what to do on receipt, and documenting every complaint with its original details. Explains sorting each complaint as a potential defect, possible falsification, or another issue sent to its owner, such as a suspected adverse event, and assessing the validity and extent of every reported defect with quality risk management. Shows the complaint log with a recorded assessment, one intake form for every source with 'could this be falsified' as a set question, links with the safety team, and three myths. It ends with a recap and three practice questions.

What you will be able to do

• Document a complaint fully on receipt
• Sort complaints into defect, possible falsification or another issue
• Assess a reported defect's validity and extent using risk

Why it matters

A complaint recorded and assessed properly at the start decides whether a falsified pack is caught or missed.

Practice: Practice: Receiving and assessing complaints · 3 questions

Follows JKL Pharma Europe's investigation team after three pharmacies in Madrid and Lisbon report chipped and discoloured metformin tablets, all from batch M-2604. Covers the nine points paragraph 8.9 says procedures must address, from describing the defect to corrective actions and their effect. Shows the work done: the Dublin laboratory comparing returned tablets with retention samples, as Annex 19 allows, the batch record showing a coating pan speed alarm, and a look-back finding two older reports each closed as a single event. Explains checking other batches and products that share materials or equipment, reviewing previous reports for recurring problems, a day-by-day timeline, and an investigation form so no point is skipped. It ends with a recap and three practice questions.

What you will be able to do

• List the points a defect investigation must address
• Use samples and records to find the extent of a defect
• Check other batches and products that may share the defect

Why it matters

Looking beyond the reported batch finds the other affected stock before it reaches more patients.

Practice: Practice: Investigating a quality defect · 3 questions

Returns to JKL's chipped metformin tablets, where a first draft blames an operator who missed a coating pan alarm and the Dublin quality reviewer asks why the alarm was easy to miss. Covers paragraph 8.16: root cause analysis matched to the risk, and addressing the most likely causes when the true cause cannot be found. Explains formally justifying human error without overlooking process, procedural or system problems. Works the steps on screen: define the defect in two batches coated in the same pan, gather batch records, alarm logs, maintenance records and operator interviews, find pan speed drops in both batches, and ask why. Ends the method with CAPA effectiveness checks with a date and owner, and monthly and yearly trend reviews. It ends with a recap and three practice questions.

What you will be able to do

• Match the depth of root cause analysis to the risk
• Justify human error without overlooking system causes
• Set CAPA with effectiveness checks and trend defect records

Why it matters

Asking why, not only who, stops the same defect coming back after another round of retraining.

Practice: Practice: Root cause and CAPA · 3 questions

Joins JKL Pharma Europe's defect team on day three of the metformin case, with two affected batches and an unfinished investigation, split between waiting for certainty and acting now. Covers paragraph 8.13: decisions that reflect the level of risk and the seriousness of non-compliance, taken in time even when information is incomplete. Explains the risk levels EU authorities use, judging the chipped tablets as moderate risk, and options from quarantine and stopping release to recalls and warnings, chosen in proportion. Shows bringing the Qualified Person in from day one, weighing the risk of shortage, and a decision log recording what was decided, when, by whom and on what information. Clears three decision myths. It ends with a recap and three practice questions.

What you will be able to do

• Make a timely decision on the risk known so far
• Choose an action in proportion to the risk
• Weigh the risk of shortage and document each decision

Why it matters

Acting at the right time on the known risk keeps defective packs off the shelves while the investigation continues.

Practice: Practice: Risk-based decisions and the QP · 3 questions

Joins JKL on day five of the metformin case, with a pharmacy-level recall of two batches sent to Spain, Portugal and Ireland, and part of one batch exported to a Gulf market. Covers paragraph 8.15: reporting defects that may lead to a recall or supply restriction in good time to the holder and all concerned authorities, with the countries of destination. Explains informing authorities before a recall, except in very serious cases, agreeing recall depth, classes one to three, and how alerts pass between countries. Shows JKL's notification, which mirrors the fields of the rapid alert form, a notification log covering exports, and out-of-hours authority contacts. Clears three myths, including that telling the home authority is enough. It ends with a recap and three practice questions.

What you will be able to do

• Identify every authority that must be told about a defect
• Agree the depth of a recall with the authorities
• Explain recall classes and the rapid alert system

Why it matters

Telling every concerned authority in good time, including export markets, avoids them hearing of a defect first from elsewhere.

Practice: Practice: Informing the competent authorities · 3 questions

Starts late on a Friday as JKL's metformin recall is agreed with Spain, Portugal and Ireland, when distribution records show wholesalers with office numbers only, and the team drives to two premises on Saturday. Covers written recall procedures that can start promptly and at any time, distribution records with batch numbers, expiry dates, product names by country, form, strength and authorisation number, and treating any retrieval for a defect as a recall. Explains notifying customers, stopping supply, the cascade through wholesalers, recall notices in each language, holding recalled stock securely, and formal disposition. Shows a live returns count, a progress log kept until closure, and the final report reconciling delivered and recovered quantities. Clears three recall myths. It ends with a recap and three practice questions.

What you will be able to do

• Check that distribution records work outside office hours
• Run the steps of a recall from notice to cascade
• Reconcile delivered and recovered quantities in a final report

Why it matters

Records and procedures that work at any hour mean a Friday night recall starts at once, not on Monday.

Practice: Practice: Running a recall · 3 questions

Opens with paragraph 8.30: recall arrangements evaluated periodically, in and out of office hours, with mock recalls considered and results documented and justified. Compares office-hours and out-of-hours tests, then follows a rehearsal at JKL Pharma Europe measured against targets set in advance: the team assembled within fifty minutes, the customer list was ready in two hours, ninety-eight percent of the batch was located, and eleven of twelve customers answered. Shows what worked and the gaps: medical samples missing from distribution records and one changed phone number, with the fixes documented. Covers the evidence inspectors ask for, three testing myths, a checklist for your company, and the final exam with its 60% mark.

What you will be able to do

• Plan a recall test for office hours and out of hours
• Measure a rehearsal against targets set in advance
• Turn rehearsal findings into documented corrective actions

Why it matters

A rehearsal that finds gaps lets you fix them before a real recall depends on them.

Practice: Practice: Testing recalls, a rehearsal and the exam · 3 questions